Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1999 3
2000 1
2001 2
2002 1
2004 1
2005 1
2008 1
2010 2
2011 2
2012 1
2013 1
2014 1
2016 1
2017 3
2018 4
2019 3
2020 2
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.
Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A. Khoury R, et al. Among authors: lecesne a. Int J Mol Sci. 2023 Jun 2;24(11):9674. doi: 10.3390/ijms24119674. Int J Mol Sci. 2023. PMID: 37298631 Free PMC article. Review.
KRASG12C mutation in metastatic colorectal cancer: a new target.
Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Lecesne A. Ibrahim R, et al. Among authors: lecesne a. Future Oncol. 2023 Aug;19(24):1641-1643. doi: 10.2217/fon-2023-0223. Epub 2023 Aug 21. Future Oncol. 2023. PMID: 37602398 No abstract available.
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment.
Sanfilippo R, Sbaraglia M, Fabbroni C, Croce S, Ray-Coquard I, Guermazi F, Paolini B, Blanc-Durand F, Lecesne A, Chiappa V, Dei Tos AP, Casali PG. Sanfilippo R, et al. Among authors: lecesne a. Clin Cancer Res. 2023 Nov 14;29(22):4679-4684. doi: 10.1158/1078-0432.CCR-23-0692. Clin Cancer Res. 2023. PMID: 37699075
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. Ivagnès A, et al. Among authors: lecesne a. Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018. Oncoimmunology. 2017. PMID: 30524877 Free PMC article.
Interventional radiology: Role in the treatment of sarcomas.
de Baere T, Tselikas L, Gravel G, Hakime A, Deschamps F, Honoré C, Mir O, Lecesne A. de Baere T, et al. Among authors: lecesne a. Eur J Cancer. 2018 May;94:148-155. doi: 10.1016/j.ejca.2018.02.017. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29567631 Review.
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients.
Valery M, Saleh K, Ecea R, Michot JM, Ribrag V, Fizazi K, Hollebecque A, Lecesne A, Ponce S, Loriot Y, Champiat S, Baldini C, Sarkozy C, Castilla-Llorente C. Valery M, et al. Among authors: lecesne a. Cancer Chemother Pharmacol. 2023 Sep;92(3):229-233. doi: 10.1007/s00280-023-04551-6. Epub 2023 Jun 24. Cancer Chemother Pharmacol. 2023. PMID: 37354233
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Stacchiotti S, et al. Among authors: lecesne a. Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Lancet Oncol. 2019. PMID: 31331701 Clinical Trial.
Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.
Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B. Jouenne F, et al. Among authors: lecesne a. J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7. J Med Genet. 2017. PMID: 28592523 Free article.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. Martin-Broto J, et al. Among authors: lecesne a. Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18. Lancet Oncol. 2019. PMID: 30578023 Clinical Trial.
36 results